Insomnia News and Research

Latest Insomnia News and Research

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Five research teams receive $2.4 million to help breast cancer survivors

A total of $2.4 million has been awarded to five research teams in the Canadian Breast Cancer Research Alliance/Canadian Breast Cancer Foundation Special Research Competition on Psychosocial Aspects of Breast Cancer.

15 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Depomed, Inc. announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.

12 Oct 2009

New soy germ-based ingredient improves menopausal symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women.

9 Oct 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Orexigen's Empatic Phase 2b results demonstrate weight loss

Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.

1 Oct 2009

Alexza enters into agreement with institutional investors to raise $19.7 million

Alexza Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement with various institutional investors to raise $19.7 million in a private placement of its common stock.

1 Oct 2009

Estrogen withdrawal may play a significant role in joint pain during breast cancer treatment

Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines. New University of Pennsylvania School of Medicine research, however, has uncovered patterns that may help clinicians identify and help women at risk of these symptoms sooner in order to increase their chances of sticking with their treatment regimen.

29 Sep 2009

Recipients of the Lundbeck Neonatal Nursing Career Path Scholarship announced

The National Association of Neonatal Nurses (NANN) is proud to announce the recipients of the Lundbeck Neonatal Nursing Career Path Scholarship. The program, made possible through a grant from Lundbeck Inc. (formerly Ovation Pharmaceuticals), supports clinical neonatal nurses who seek to advance their education and become neonatal nurse practitioners.

25 Sep 2009

FDA grants priority review for Cephalon's sNDA

Cephalon, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV], which was filed in June of this year.

25 Sep 2009

Bioscience Research offers mental health care at no cost

Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job.

22 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

FDA issues a complete response letter for Sanofi-aventis' eplivanserin NDA

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company's New Drug Application (NDA) for eplivanserin (Ciltyri(R)). Eplivanserin was reviewed as a potential treatment for patients with chronic insomnia characterized by difficulties with sleep maintenance.

17 Sep 2009

Transcendental Meditation aids students diagnosed with ADHD

A panel of physicians and scientists will report on the benefits of a simple meditation practice for aiding students diagnosed with ADHD during a national medical webinar, which will be hosted by the David Lynch Foundation on Wednesday, September 30, 12 noon (ET).

16 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

Hebrew University researchers' discovery may lead to treatments for various states of loss of consciousness

A new understanding of how anesthesia and anesthesia-like states are controlled in the brain opens the door to possible new future treatments of various states of loss of consciousness, such as reversible coma, according to Hebrew University of Jerusalem scientists.

14 Sep 2009